

## An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Lymphoma and Multiple Myeloma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following observations was made in the Phase III GALLIUM study evaluating obinutuzumab- versus rituximab-based induction and maintenance therapy for previously untreated follicular lymphoma?
  - a. No difference in PFS
  - b. PFS favoring rituximab
  - c. PFS favoring obinutuzumab
2. The majority of patients with del(17p) CLL
  - a. Present up front with the 17p deletion
  - b. Acquire the 17p deletion over the course of their disease
3. Tumor lysis syndrome is an adverse event associated with venetoclax therapy for patients with CLL.
  - a. True
  - b. False
4. \_\_\_\_\_ is an FDA-approved orally bioavailable inhibitor of the delta isoform of PI3 kinase for the treatment of relapsed CLL.
  - a. Copanlisib
  - b. Ibrutinib
  - c. Idelalisib
  - d. TGR-1202
5. The results of the Phase III POLLUX trial of lenalidomide and dexamethasone with or without daratumumab for patients with MM who have received 1 or more prior lines of therapy failed to demonstrate a statistically significant improvement in PFS with the addition of daratumumab.
  - a. True
  - b. False
6. Which of the following statements is false about the use of proteasome inhibitors in the management of MM?
  - a. Carfilzomib is associated with shortness of breath
  - b. In comparison to bortezomib, carfilzomib is associated with a higher incidence of neuropathy
  - c. Ixazomib is an orally bioavailable proteasome inhibitor
  - d. All of the above
  - e. None of the above
7. Lenalidomide-induced diarrhea in patients with MM may be caused by bile acid malabsorption, which may be treated with bile acid sequestrants like colestipol.
  - a. True
  - b. False
8. For frail, elderly patients with MM who have received at least 1 prior line of therapy, the administration of elotuzumab may be considered before daratumumab because \_\_\_\_\_.
  - a. Elotuzumab is easier to tolerate
  - b. Elotuzumab is faster to infuse
  - c. Both a and b
9. Acalabrutinib is a(n) \_\_\_\_\_.
  - a. Anti-PD-1/PD-L1 antibody
  - b. BTK inhibitor
  - c. Immunomodulatory drug
10. Because it is universally expressed on malignant plasma cells, which of the following antigens is an attractive target for CAR T-cell-directed therapy in MM?
  - a. B-cell maturation antigen (BCMA)
  - b. CD19
  - c. CD33